Business Context and Reporting Period
Company: OS Therapies Inc (OSTX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2026
Event: Entry into a Material Definitive Agreement regarding a Warrant Exercise Inducement.
The Company, an emerging growth company, entered into inducement offer letter agreements with less than 10 accredited investors holding existing warrants. The transaction aims to raise capital to support regulatory efforts for OST-HER2 (lung metastatic osteosarcoma), fund preparations for the spinoff of its subsidiary OS Animal Health, and cover general corporate purposes.
Key Financial Metrics and Transaction Details
- Expected Gross Proceeds: Approximately $7.5 million.
- Existing Warrants Involved: Up to 5,382,148 shares.
- Inducement Exercise Price: $1.40 per share (reduced from original terms).
- New Warrants Issued: Up to 5,382,148 shares at an exercise price of $1.40 per share.
- New Warrant Term: 5 years from issuance; immediately exercisable.
- Solicitation Agent Fees: 8.0% of total gross cash proceeds plus up to $25,000 for legal and other expenses.
- Inducement Period: January 10, 2026, to February 10, 2026.
Note: This filing does not provide standard financial metrics such as revenue, net income, operating cash flow, or total debt for a specific reporting period.
Material Changes and Transaction Mechanics
The primary material change is the modification of warrant terms to incentivize cash exercise:
- Price Reduction: Holders agreed to exercise existing warrants at a reduced price of $1.40 per share.
- Beneficial Ownership Limitation: If exercising at $1.40 would cause a holder to exceed beneficial ownership limits, the holder may pre-fund the exercise at $1.399 per share ($1.40 less $0.001). Upon pre-funding, the remaining exercise price for those warrants is reduced to $0.001 per share.
- Registration: Shares underlying existing warrants are registered under Forms S-1 and S-3. The Company agreed to file a new Form S-3 for the resale of shares underlying the New Warrants within 30 days of closing.
Outlook, Risks, and Contingencies
- Use of Proceeds: Funding U.S. and international regulatory/pre-commercial efforts for OST-HER2, OS Animal Health spinoff preparations, and general corporate purposes.
- Termination Risk: The Company may cancel a holder's exercise or pre-funding if funds are not received within two business days following the Termination Date (February 10, 2026).
- Waiver of Rights: Upon cancellation, holders irrevocably waive rights to future exercise price adjustments or economic terms arising from transactions after the Final Funding Date.
- Forced Exercise: New Warrants include a provision allowing the Company to force cash exercise if the stock price exceeds 300% of the exercise price for 20 consecutive trading days.
- Ownership Caps: Holders are generally limited to owning 4.99% (or up to 9.99% with notice) of outstanding common stock post-exercise.
Investor Verification Checklist
- Verify the actual gross proceeds received versus the expected $7.5 million after the Inducement Period closes.
- Confirm the effectiveness of the new Form S-3 registration statement for the New Warrants within the 60-day window.
- Monitor the progress of the OS Animal Health spinoff transaction preparations.
- Review the impact of the 8.0% solicitation fee on the net capital available for operations.
- Check for any cancellations of warrant exercises due to failure to meet the Final Funding Date.